SCH 412348Alternative Names: SCH-412348; SCH-58261
Latest Information Update: 30 Oct 2009
At a glance
- Originator Schering-Plough
- Class Antiparkinsonians
- Mechanism of Action Adenosine A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease